

Supplementary Tables

Supplementary Table S1: STROBE Checklist of items that should be included in reports of cross-sectional studies

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1-3
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3-4
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5
Objectives	3	State specific objectives, including any prespecified hypotheses	5
Methods			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6-7
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	7
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	8-11
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	10-11
Bias	9	Describe any efforts to address potential sources of bias	6-14
Study size	10	Explain how the study size was arrived at	8
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	10-11
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	13-14
		(b) Describe any methods used to examine subgroups and interactions	13-14

		(c) Explain how missing data were addressed	14
		(d) If applicable, describe analytical methods taking account of sampling strategy	NA
		(e) Describe any sensitivity analyses	14
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	14-15
		(b) Give reasons for non-participation at each stage	14-15
		(c) Consider use of a flow diagram	NA
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	15-20
		(b) Indicate number of participants with missing data for each variable of interest	18-20
Outcome data	15*	Report numbers of outcome events or summary measures	18-20
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	16-17; 21-22
		(b) Report category boundaries when continuous variables were categorized	18-20
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	17
Discussion			
Key results	18	Summarise key results with reference to study objectives	23
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	28-29
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	23-28
Generalisability	21	Discuss the generalisability (external validity) of the study results	25-29
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	30

Supplementary Table S2: Demographic characteristics of total inpatients; including non-eligible, eligible non-consenting and eligible consenting subgroups (number (%) unless otherwise stated)

	Total	Large Regional (General)	Major Regional (General)	Large Metro. (General)	Major Metro. (Speciality)	Major Metro. (General)
Total Inpatients	1146	26	110	151	340	519
Age (SD) years	63(19)	52(19)	66(19)	66(20)	67(19)	59(19)
Missing data	222 (19%)	2 (8%)	8 (7%)	0	68 (20%)	144 (28%)
Male sex	549 (55%)	16 (64%)	66 (60%)	81 (54%)	161 (51%)	225 (57%)
Missing data	152 (13%)	1 (4%)	0	0	25 (7%)	126 (24%)
Non-eligible	263 (23%)	5 (19%)	18 (16%)	31 (21%)	68 (20%)	141 (27%)
Age (SD) years	71(20)	64(27)	76(14)	73(22)	80(11)	59(22)
Missing data	149 (54%)	2 (40%)	3 (17%)	0	38 (56%)	106 (75%)
Male sex	82 (57%)	3 (75%)	10 (56%)	15 (48%)	24 (48%)	30 (73%)
Missing data	119 (45%)	1 (20%)	0	0	18 (26%)	100 (71%)
Eligible	883 (77%)	21 (81%)	92 (84%)	120 (79%)	272 (80%)	378 (73%)
Age (SD) years	62(19)	50(18)	64(19)	64(19)	65(19)	59(19)
Missing data	72 (8%)	0	5 (5%)	0	30 (11%)	37(10%)
Male sex	467 (55%)	13 (62%)	56(61%)	66(55%)	137 (52%)	195 (55%)
Missing data	32(4%)	0	0	0	7 (3%)	35 (9%)
Non-consenting	150 (17%)	0	10 (11%)	30 (25%)	40 (15%)	70 (19%)
Age (SD) years	59(22)	0	67(14)	66(20)	62(29)	51(19)
Missing data	70 (47%)	0	5 (50%)	0	29 (73%)	36 (51%)
Male sex	59 (49%)	0	4 (40%)	20 (67%)	10 (30%)	25 (53%)
Missing data	30 (20%)	0	0	0	7 (17%)	23 (33%)
Consenting	733 (83%)	21 (100%)	82 (89%)	90 (75%)	232 (85%)	308 (81%)
Age (SD) years	62(19)	50(18)	64(19)	63(18)	66(18)	60(18)
Missing data	2 (<1%)	0	0	0	1 (<1%)	1 (<1%)
Male sex (%)	408 (56%)	13 (62%)	52 (63%)	46 (51%)	127 (55%)	170 (56%)
Missing data	2 (<1%)	0	0	0	1 (<1%)	1 (<1%)

Metro: Metropolitan; SD: Standard deviation.

Supplementary Table S3: Univariate analyses for participants with a foot-related condition as a primary reason or secondary reason for admission

Variables	Primary Foot-related Condition Admission			Secondary Foot-related Condition Admission		
	n (%)	Odds ratio [95% CI]	p Value	n (%)	Odds ratio [95% CI]	p Value
Participants	54 (7.4%)			28 (3.8%)		
Ward						
Medical	18 (33.3%)	1.00		22 (78.6%)	1.00	
Surgical	36 (66.7%)	3.71 [2.06-6.67]	<0.001**	6 (21.4%)	0.45 [0.17-1.11]	0.083*
Demographics						
Age (SD) years	621.(17.0)	1.00 [0.99-1.02]	0.962	63.5(19.3)	1.01 [0.98-1.03]	0.663
Age groups			0.488			0.952
18-40 years	6 (11.1%)	1.00		4 (14.3%)	1.00	
41-60 years	14 (25.9%)	1.40 [0.52-3.74]	0.509	6 (21.4%)	0.87 [0.24-3.17]	0.837
61-80 years	28 (51.9%)	1.69 [0.68-4.19]	0.261	13 (46.4%)	1.14 [0.36-3.56]	0.826
81+ years	6 (11.1%)	0.94 [0.29-3.00]	0.913	5 (17.9%)	1.18 [0.31-4.52]	0.806
Male sex	33 (61.1%)	1.27 [0.72-2.23]	0.416	14 (50.0%)	0.78 [0.37-1.67]	0.528
Social Determinants						
Socioeconomic Status			0.635			0.714
Most disadvantaged	9 (17.6%)	1.00		5 (17.9%)	1.00	
Second most disadvantaged	15 (29.4%)	1.08 [0.45-2.56]	0.868	4 (14.3%)	0.50 [0.29-3.72]	0.311
Middle	6 (11.8%)	0.67 [0.23-1.97]	0.471	5 (17.9%)	1.04 [0.29-3.72]	0.948
Second least disadvantaged	14 (27.5%)	0.64 [0.27-1.53]	0.316	11 (39.3%)	0.93 [0.32-2.75]	0.898
Least disadvantaged	7 (13.7%)	0.69 [0.25-1.92]	0.477	3 (10.7%)	0.53 [0.12-2.29]	0.399
Geographic Remoteness			0.291			0.592
Major city	27 (52.9%)	1.00		18 (64.3%)	1.00	
Inner regional area	12 (23.5%)	1.29 [0.64-2.61]	0.485	4 (14.3%)	0.62 [0.21-1.87]	0.397
Outer regional area	9 (17.6%)	2.39 [1.07-5.33]	0.034	5 (17.9%)	1.90 [0.68-5.30]	0.221
Remote area	0	0	NA	1 (3.6%)	0.80 [0.10-6.20]	0.830
Very remote area	3 (5.9%)	1.89 [0.54-6.67]	0.323	0	0	NA
<Year 10 Education Level	34 (63.0%)	1.49 [0.84-2.64]	0.174*	15 (53.6%)	0.98 [0.46-2.09]	0.960
Indigenous	3 (5.6%)	1.23 [0.36-4.15]	0.741	0	0	NA
Born overseas	6 (11.1%)	0.42 [0.18-1.00]	0.051*	5 (17.9%)	0.76 [0.26-2.04]	0.588
Medical Condition History						
Diabetes	15 (27.8%)	1.28 [0.69-2.38]	0.438	19 (67.9%)	7.62 [3.38-17.17]	<0.001**
Hypertension	27 (50.0%)	1.05 [0.60-1.82]	0.876	15 (53.6%)	1.21 [0.57-2.58]	0.620
Dyslipidaemia	13 (24.1%)	0.66 [0.35-1.25]	0.201	10 (35.7%)	1.19 [0.54-2.63]	0.661
Myocardial Infarct	7 (13.0%)	0.58 [0.26-1.31]	0.189*	6 (21.4%)	1.10 [0.44-2.77]	0.838
Cerebrovascular Accident	7 (13.0%)	1.15 [0.50-2.63]	0.745	3 (10.7%)	0.91 [0.27-3.09]	0.882
Chronic Kidney Disease	6 (11.1%)	0.90 [0.37-2.16]	0.810	7 (25.0%)	2.53 [1.04-6.14]	0.040**
Cancer	11 (20.4%)	0.81 [0.41-1.61]	0.546	6 (21.4%)	0.87 [0.35-2.19]	0.770
Arthritis	23 (42.6%)	1.27 [0.72-2.22]	0.412	11 (39.3%)	1.09 [0.50-2.36]	0.832

Depression	17 (31.5%)	1.33 [0.73-2.43]	0.347	10 (35.7%)	1.61 [0.73-3.55]	0.239
Acute foot trauma	15 (27.8%)	23.36 [10.06-54.23]	<0.001**	3 (10.7%)	3.56 [1.00-12.64]	0.050*
Smoker	11 (20.4%)	1.61 [0.80-3.24]	0.180*	6 (21.4%)	1.69 [0.67-4.27]	0.268
Ex-Smoker	21 (38.9%)	0.89 [0.51-1.57]	0.689	10 (35.7%)	0.78 [0.35-1.71]	0.529
Self-care Ability						
Mobility impairment	24 (44.4%)	1.68 [0.96-2.94]	0.071*	17 (60.7%)	3.27 [1.51-7.10]	0.003**
Vision impairment	9 (16.7%)	1.14 [0.54-2.40]	0.733	6 (21.4%)	1.57 [0.62-3.96]	0.341
Footwear worn: Inside			0.984			0.293
Low risk footwear	6 (11.3%)	1.00		3 (11.1%)	1.00	
Moderate risk footwear	18 (34.0%)	0.92 [0.35-2.40]	0.862	14 (51.9%)	1.46 [0.41-5.22]	0.559
High risk footwear	10 (18.9%)	0.97 [0.34-2.77]	0.953	2 (7.4%)	0.38 [0.06-2.32]	0.294
No footwear worn	19 (35.8%)	1.05 [0.41-2.73]	0.919	8 (29.6%)	0.88 [0.23-3.39]	0.850
Footwear worn: Outside			0.929			0.558
Low risk footwear	28 (53.8%)	1.00		11 (40.7%)	1.00	
Moderate risk footwear	4 (7.7%)	0.72 [0.25-2.12]	0.551	4 (14.8%)	1.92 [0.50-6.20]	0.275
High risk footwear	19 (36.5%)	1.05 [0.57-1.93]	0.871	12 (44.4%)	1.72 [0.75-3.96]	0.203
No footwear worn	1 (1.9%)	0.91 [0.12-7.20]	0.913	0	0	NA
Past Foot Treatment						
Yes	34 (63.0%)	3.50 [1.97-6.22]	<0.001**	19 (67.9%)	4.17 [1.86-9.36]	0.001**
Podiatry	20 (37.0%)	1.91 [1.07-3.41]	0.029**	14 (50.0%)	3.25 [1.52-6.95]	0.002**
GP	25 (46.3%)	7.75 [4.29-13.98]	<0.001**	9 (32.1%)	3.50 [1.53-7.99]	0.003**
Surgeon	19 (35.2%)	21.14 [10.11-44.19]	<0.001**	3 (10.7%)	2.44 [0.70-8.51]	0.160*
Physician	4 (7.4%)	3.12 [1.01-9.61]	0.048**	2 (7.1%)	2.78 [0.61-12.56]	0.185*
Nurse	10 (18.5%)	15.21 [6.01-38.46]	<0.001**	3 (10.7%)	4.86 [1.34-17.65]	0.016**
Orthotist	4 (7.4%)	NA	NA	0	0	NA
Other	0	0	NA	0	0	NA
Foot Disease History						
Previous Peripheral Neuropathy	29 (37.0%)	4.43 [2.43-8.07]	<0.001**	6 (21.4%)	1.78 [0.70-4.51]	0.224
Previous PAD	28 (51.9%)	9.44 [5.24-17.02]	<0.001**	9 (32.1%)	3.29 [1.45-7.51]	0.005**
Previous foot ulcer	26 (48.1%)	12.74 [6.91-23.49]	<0.001**	12 (42.9%)	8.04 [2.63-17.78]	<0.001**
Previous amputation	15 (27.8%)	16.97 [2.74-37.22]	<0.001**	3 (10.7%)	3.00 [0.85-10.57]	0.086*
Foot Risk Factors						
Peripheral Neuropathy	24 (45.3%)	3.28 [1.85-5.82]	<0.001**	11 (40.7%)	2.55 [1.16-5.61]	0.020**
PAD			<0.001**			<0.001**
Nil PAD	25 (47.2%)	1.00		12 (44.4%)	1.00	
Mild PAD	0	0	NA	4 (14.8%)	2.89 [0.91-9.21]	0.073*
Moderate PAD	10 (18.9%)	5.37 [2.41-11.93]	<0.001**	7 (25.9%)	7.46 [2.80-19.91]	<0.001**
Critical PAD	18 (34.0%)	26.40 [11.94-58.39]	<0.001**	4 (14.8%)	6.47 [1.97-21.30]	0.002**
Foot deformity	16 (32.0%)	.170 [0.91-3.18]	0.094*	7 (25.9%)	1.22 [0.51-2.95]	0.653
Foot Disease						
Current foot ulcer	24 (44.4%)	23.86 [12.03-47.30]	<0.001**	12 (42.9%)	14.78 [6.48-33.69]	<0.001**
Current foot infection	19 (40.4%)	91.06 [31.70-261.58]	<0.001**	3 (11.5%)	4.20 [1.17-15.09]	0.028**
Foot Risk Status			<0.001**			<0.001**

Low risk	2 (3.7%)	1.00		5 (17.9%)	1.00	
At risk	1 (1.9%)	2.01 [0.18-22.41]	0.569	4 (14.3%)	3.29 [0.87-12.46]	0.080*
High risk	12 (22.2%)	27.40 [6.04-124.41]	<0.001**	5 (17.9%)	4.23 [1.20-14.88]	0.025**
Acute	39 (72.2%)	319.94 [73.33-1395.90]	<0.001**	14 (50.0%)	23.69 [8.20-68.44]	<0.001**

* $p < 0.2$; ** $p < 0.05$; GP: General Practitioner; PAD: Peripheral Arterial Disease; SD: Standard deviation.

Supplementary Table S4: Data collector pre- and post-training testing

QDFD Field	Pre-Training		Post-Training		<i>p</i> Value
	n	%	n	%	
Data Collectors Completing	22		27		
Demographics					
Study Code	3	13.6	27	100	NA
Hospital	15	68.2	27	100	0.002*
Ward	13	59.1	27	100	<0.001*
Eligible	20	90.9	27	100	0.196
Consent	21	95.5	27	100	0.449
Sex	22	100	27	100	1.00
Age	22	100	27	100	1.00
Social Determinants					
Postcode	22	100	27	100	1.00
Indigenous	20	90.9	27	100	0.196
Born Overseas	22	100	27	100	1.00
Highest Education Level	19	86.4	27	100	0.084
Medical Conditions History					
Diabetes	22	100	27	100	1.00
Diabetes duration #	22	100	27	100	1.00
HbA1c result #	21	95.5	26	96.3	1.00
Hypertension	22	100	27	100	1.00
Dyslipidaemia	22	100	27	100	1.00
Myocardial Infarct	17	77.3	27	100	0.014*
CVA	21	95.5	27	100	0.449
CKD	20	90.9	27	100	0.196
ESKD	22	100	27	100	1.00
Cancer	22	100	27	100	1.00
Arthritis	21	95.5	27	100	0.449
Depression	22	100	27	100	1.00
Acute foot trauma	22	100	22	81.5	0.056
Smoker	22	100	27	100	1.00
Ex-smoker	21	95.5	27	100	1.00
Other (non-listed)	17	77.3	27	100	0.014*
Self-care Ability					
Mobility impairment	22	100	26	96.3	1.00
Vision impairment	11	50.0	27	100	<0.001*
Footwear worn: Inside	20	90.9	27	100	0.196
Footwear worn: Outside	19	86.4	27	100	0.084
Past Foot Treatments					
Yes	22	100	27	100	1.00

Podiatrist	20	90.9	27	100	0.196
GP	22	100	27	100	1.00
Nurse	21	95.5	27	100	0.449
Orthotist	22	100	27	100	1.00
Physician	22	100	27	100	1.00
Surgeon	19	86.4	27	100	0.084
Other	20	90.9	27	100	0.196
Foot Disease History					
Previous Peripheral Neuropathy	22	100	26	96.3	1.00
Previous PAD	20	90.9	27	100	0.196
Previous foot ulcer	22	100	27	100	1.00
Previous amputation	22	100	27	100	1.00
Foot Risk Factors					
Peripheral Neuropathy	22	100	26	96.3	1.00
PAD	20	90.9	26	96.3	0.581
Foot deformity	21	95.5	21	77.8	0.112
Foot Disease					
Acute Charcot	22	100	26	96.3	1.00
Current foot ulcer	22	100	27	100	1.00
Current foot infection *	18	81.8	27	100	0.034*
Current amputation	21	95.5	26	96.3	1.00
Foot risk status classification	19	86.4	27	100	0.084
Ulcer type *	14	63.6	23	85.2	0.104
Ulcer location:	1	4.5	23	85.2	NA
Ulcer surface	1	4.5	23	85.2	NA
Combined surface area mm ² #	19	86.4	25	92.6	0.646
UTWCS grade #	10	45.5	25	92.6	<0.001*
Foot-related Condition Admission					
Reason for admission	21	95.5	27	100	0.449
Total					
Mean %	87.2%		97.7%		< 0.001*
Mean Score (SD)	49.7(4.2)		55.7(1.8)		< 0.001*
Median (IQR)	51 (48.75 - 52.25)		56 (55.0 - 57.0)		< 0.001*

**p* Value of < 0.05; CKD: Chronic Kidney Disease; CVA: Cardiovascular Accident; ESKD End Stage Kidney Disease; GP: General Practitioner; IQR: Interquartile Range; NA: Not applicable to test as the assumption of Chi-squared test is violated as 2 cells had expected count < 5; PAD: Peripheral Arterial Disease; SD: Standard Deviation; UTWCS: University of Texas Wound Classification System.

Supplementary Table S5: Agreement between sub-sample of participants' study data and medical records

QHRFF Item	n	Study Data	Medical Records	%	K (SE)	Strength of Agreement
Demographics						
Age#	44	--	--		1.00 (1.00 – 1.00)	Strong
Male Sex	44	25	25	100	1.00 (0.01)	Near Perfect
Social Determinants						
Postcode*	40	--	--	92.5	0.92 (0.05)	Near Perfect
Indigenous Status	28	1	1	100	1.00 (0.01)	Near Perfect
Born overseas	27	5	5	100	1.00 (0.01)	Near Perfect
Medical Condition History						
Diabetes	28	7	6	96.4	0.90 (0.10)	Near Perfect
Hypertension	28	17	14	82.1	0.64 (0.14)	Substantial
Dyslipidaemia	28	11	9	92.9	0.85 (0.10)	Near Perfect
Myocardial Infarct	28	8	4	85.7	0.59 (0.17)	Moderate
CVA	28	3	2	89.3	0.34 (0.29)	Fair
CKD	28	3	4	96.4	0.84 (0.16)	Near Perfect
ESKD	28	0	0	100	--	--
Cancer	28	7	3	85.7	0.53 (0.19)	Moderate
Arthritis	28	12	11	89.3	0.78(0.12)	Substantial
Depression	28	8	5	82.1	0.51 (0.18)	Moderate
Acute foot trauma	28	1	0	96.4	--	--
Smoker	28	8	8	100	1.0 (0.01)	Near Perfect
Ex-smoker	28	11	2	67.9	0.23 (0.13)	Fair
Foot-related Condition Admission						
Reason for admission*	28	1	1	100	1.00 (0.01)	Near Perfect

*Weighted Kappa used for ordinal data; #Intraclass correlation (Standard Deviation (SD)) for continuous data; -- = Measure of agreement was unable to be calculated because at least one variable was a constant or was a continuous variable; % = Percentage agreement; CKD: Chronic Kidney Disease; CVA: Cerebrovascular Accident; ESKD: End Stage Kidney Disease; K = Kappa (Standard Error (SE))